Is Smith-Lemli-Opitz Syndrome contagious?

Smith-Lemli-Opitz syndrome is a genetic condition and is absolutely not contagious; it cannot be spread through touch, bodily fluids, or any form of social contact. The disorder is caused by an inherited metabolic error in cholesterol synthesis, meaning it is biologically impossible for it to be transmitted from one person to another.

What is the underlying cause of Smith-Lemli-Opitz syndrome?

Smith-Lemli-Opitz syndrome (SLOS) is a rare autosomal recessive genetic disorder. It is caused by mutations in the DHCR7 gene, which provides instructions for making an enzyme called 7-dehydrocholesterol reductase. This enzyme is responsible for the final step in the body's natural production of cholesterol. Because individuals with Smith-Lemli-Opitz syndrome have a deficiency in this enzyme, they are unable to produce sufficient cholesterol, which is essential for normal fetal development and ongoing cellular function. Because the cause is strictly genetic, it is impossible for someone to "catch" or develop this condition through exposure to another affected individual.

Why might there be confusion regarding the contagion of Smith-Lemli-Opitz syndrome?

Misunderstandings often arise because Smith-Lemli-Opitz syndrome can present with physical symptoms or developmental delays that may appear unfamiliar to the general public. In some rare disease communities, there is a historical stigma where people mistakenly assume that any condition causing physical differences or neurological challenges must be infectious. However, Smith-Lemli-Opitz syndrome is strictly an internal metabolic process. There is no risk to siblings, classmates, or caregivers in sharing living spaces, meals, or physical affection with someone diagnosed with Smith-Lemli-Opitz syndrome.

Are there environmental triggers that mimic contagion?

While Smith-Lemli-Opitz syndrome is not contagious, it is a complex metabolic condition. Because cholesterol is vital for membrane structure and the production of hormones and bile acids, the body’s inability to synthesize it correctly can lead to various health challenges. Families should be aware of the following factors that impact health management:

• Metabolic Stress: Illnesses or periods of fasting can place additional strain on the body, as individuals with Smith-Lemli-Opitz syndrome may have difficulty maintaining cholesterol homeostasis during physical stress.


• Dietary Considerations: While diet is not a "trigger" for the disease itself, clinical management often involves cholesterol supplementation to support the body’s needs.


• Photosensitivity: Some individuals with Smith-Lemli-Opitz syndrome may experience increased sensitivity to sunlight due to the accumulation of cholesterol precursors in the skin, which is a clinical feature, not an infectious symptom.

How common is Smith-Lemli-Opitz syndrome?

Smith-Lemli-Opitz syndrome is estimated to affect approximately 1 in 20,000 to 60,000 newborns, though the prevalence varies by population. Within the DiseaseMaps community, 61 people with Smith-Lemli-Opitz syndrome have joined to share their experiences, helping to reduce the isolation often felt by families. Understanding the genetic nature of the condition is the first step in dismantling the stigma surrounding this or any other rare genetic disorder.

Next steps

• Consult with a clinical geneticist to understand the inheritance pattern of Smith-Lemli-Opitz syndrome within your family.


• Work with a metabolic specialist or endocrinologist to manage cholesterol levels and overall health.


• Connect with the 61 other community members on DiseaseMaps.org to share resources and emotional support.


• Educate school staff, friends, and family members that Smith-Lemli-Opitz syndrome is strictly genetic and poses no risk to others.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Smith-Lemli-Opitz syndrome overview.


• Orphanet: Rare disease database entry for Smith-Lemli-Opitz syndrome (ORPHA:819).


• OMIM (Online Mendelian Inheritance in Man): Entry #270400 (7-Dehydrocholesterol Reductase Deficiency).


• Smith-Lemli-Opitz Foundation: Patient resources and educational materials.